Abstract
C-C chemokine receptor type 2 (CCR2) belongs to large GPCR family and it plays a critical role in cognitive function. Inhibition of CCR2 is important for autoimmune diseases including atherosclerosis, pain, and metabolic diseases. 3D structure of this receptor was not solved yet. In the current study, 3D structure of the CCR2 is predicted using recently solved high resolution crystal structure of C-C chemokine receptor type 5 (CCR5) which shares a high amino acid sequence homology with CCR2. Derived model firstly refined with molecular dynamics simulations and then validated with Ramachandran plot as well as available validation tools such as PROCHECK (a program to check the sterochemical quality of protein structures). Correctness of the topology of the binding cavity of the target structure is externally tested with known CCR2 inhibitors using molecular docking simulations. In addition, in order to discover novel CCR2 inhibitors through approved drugs, high throughput virtual screening of marketed drugs against derived CCR2 model was performed.
Keywords: C-C chemokine receptor type 2 (CCR2), protein engineering, molecular docking, CCR2 inhibitors, virtual screening.
Current Enzyme Inhibition
Title:Protein Engineering Studies for C-C Chemokine Receptor Type 2 (CCR2)
Volume: 12 Issue: 2
Author(s): Ramin E. Salmas, Mine Yurtsever and Serdar Durdagi
Affiliation:
Keywords: C-C chemokine receptor type 2 (CCR2), protein engineering, molecular docking, CCR2 inhibitors, virtual screening.
Abstract: C-C chemokine receptor type 2 (CCR2) belongs to large GPCR family and it plays a critical role in cognitive function. Inhibition of CCR2 is important for autoimmune diseases including atherosclerosis, pain, and metabolic diseases. 3D structure of this receptor was not solved yet. In the current study, 3D structure of the CCR2 is predicted using recently solved high resolution crystal structure of C-C chemokine receptor type 5 (CCR5) which shares a high amino acid sequence homology with CCR2. Derived model firstly refined with molecular dynamics simulations and then validated with Ramachandran plot as well as available validation tools such as PROCHECK (a program to check the sterochemical quality of protein structures). Correctness of the topology of the binding cavity of the target structure is externally tested with known CCR2 inhibitors using molecular docking simulations. In addition, in order to discover novel CCR2 inhibitors through approved drugs, high throughput virtual screening of marketed drugs against derived CCR2 model was performed.
Export Options
About this article
Cite this article as:
Salmas E. Ramin, Yurtsever Mine and Durdagi Serdar, Protein Engineering Studies for C-C Chemokine Receptor Type 2 (CCR2), Current Enzyme Inhibition 2016; 12 (2) . https://dx.doi.org/10.2174/1573408011666150807190410
DOI https://dx.doi.org/10.2174/1573408011666150807190410 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) Rheumatoid Arthritis, Immunosenescence and the Hallmarks of Aging
Current Aging Science Dendritic Cell Homeostasis in the Regulation of Self-Reactivity
Current Pharmaceutical Design Experimental Models of Relapsing-Remitting Multiple Sclerosis: Current Concepts and Perspective
Current Neurovascular Research Advances in the Treatment of Autoimmune Diseases; Cellular Activity, Type-1/Type-2 Cytokine Secretion Patterns and their Modulation by Therapeutic Peptides
Current Medicinal Chemistry Current Status of Vitamin D Signaling and Its Therapeutic Applications
Current Topics in Medicinal Chemistry The Medical Functions of Probiotics and Their Role in Clinical Nutrition
Current Nutrition & Food Science Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design Regulation of B Cell Activation by PECAM-1: Implications for the Development of Autoimmune Disorders
Current Pharmaceutical Design Protein Tyrosine Phosphatase as Potential Therapeutic Target in various Disorders
Current Molecular Pharmacology Clinical Queries Addressed in Patients with Systemic Autoimmune Diseases. Can Cardiovascular Magnetic Resonance Give the Final Solution?
Inflammation & Allergy - Drug Targets (Discontinued) Lipid-Based Nanocarriers for RNA Delivery
Current Pharmaceutical Design Recent Patents on Immunoregulatory DNA Vaccines for Autoimmune Diseases and Allograft Rejection
Recent Patents on DNA & Gene Sequences Celastrol Inhibits Inflammatory Stimuli-Induced Neutrophil Extracellular Trap Formation
Current Molecular Medicine JAK3 Inhibitors in Organ Transplantation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery Chlorogenic Acid Suppresses a Cell Adhesion Molecule in Experimental Autoimmune Myocarditis in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Defining Peptide Sequences: From Antigenicity to Immunogenicity Through Redundancy
Current Pharmacogenomics Identification of Novel Scaffolds for IκB Kinase Beta Inhibitor via a High Throughput Screening TR-FRET Assay
Combinatorial Chemistry & High Throughput Screening “Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Current Molecular Medicine